Mifepristone
Treatment for Cushing's Syndrome
Typical Dosage: 300-1200 mg daily
Effectiveness
50%
Safety Score
55%
Clinical Trials
10
Participants
500
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
55
DangerousModerateSafe
Treatment Details
Dosage Range
300-1200 mg daily
Time to Effect
6-12 weeks
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
3.5(Treat 3.5 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
2.5(Treat 2.5 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$200,000
Monitoring:$2,000
Side Effect Mgmt:$1,500
Total Annual:$203,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$600,000/QALY
QALYs Gained
0.4
Outcome-Based Costs
Cost per Responder
$407,000
Mifepristone Outcomes
for Cushing's Syndrome
Efficacy Outcomes
Overall Effectiveness
+50%
Response Rate
+50%
Common Side Effects
Hypokalemia
+45%
Nausea/Fatigue
+35%
Hypertension
+25%
Peripheral edema
+25%
Endometrial thickening/bleeding
+25%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
7 completed trials for Mifepristone in Cushing's Syndrome
Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome
NCT01371565COMPLETEDPHASE3
4 participants
INTERVENTIONAL
Hollywood, United States +4 more
Started: Nov 1, 2010
An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome
NCT00936741COMPLETEDPHASE3
30 participants
INTERVENTIONAL
Birmingham, United States +14 more
Started: Jul 1, 2009
A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome
NCT00569582COMPLETEDPHASE3
50 participants
INTERVENTIONAL
Birmingham, United States +16 more
Started: Dec 1, 2007
Glucocorticoid Receptor Blockade With Mifepristone in Patients With Mild Adrenal Hypercortisolism
NCT01990560COMPLETEDPHASE4
8 participants
INTERVENTIONAL
New York, United States
Started: Nov 1, 2013
Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)
NCT05772169COMPLETEDPHASE4
1.11K participants
INTERVENTIONAL
Escondido, United States +35 more
Started: Mar 31, 2023
Retrospective Chart Review Study of Korlym for the Treatment of ACTH Independent Cushing's Syndrome
NCT02663609COMPLETED
24 participants
OBSERVATIONAL
Started: Oct 1, 2015
Mifepristone Effects on Glucose Intolerance in Obese/Overweight Adults
NCT01419535COMPLETEDPHASE1, PHASE2
19 participants
INTERVENTIONAL
Bethesda, United States
Started: Nov 29, 2011